APPROACHES AND SIGNIFICANCE OF TRANSDERMAL DRUG DELIVERY SYSTEMS: A REVIEW

被引:1
作者
Raghuraman, V. [1 ]
Pandey, V. P. [1 ]
机构
[1] Annamalai Univ, Fac Engn & Technol, Dept Pharm, Annamalainagar 608002, Tamil Nadu, India
关键词
Transdermal Drug Delivery Systems; Painless; Noninvasive;
D O I
10.13040/IJPSR.0975-8232.5(2).340-45
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Transdermal Drug Delivery System (TDDS) is the most innovative and Novel drug delivery systems by penetrating through the skin by increasing the scope of molecules that can be delivered. TDDS that traditionally uses a patch containing loaded drug substances pressed on to the skin is convenient, painless and non-invasive, to avoid gastro intestinal (GI) tract toxicity (peptic ulcer disease). Transdermal delivery not only provides controlled, constant administration of the drug, but also allows continuous input of drugs with short biological half-lives and eliminates pulsed entry into systemic circulation which often causes undesirable side effect. The number of medications and the ways in which they can be administered have expanded dramatically over the years. One such advancement is the development of transdermal patch delivery systems. Transdermal drug technology specialists are continuing to search for new methods that can effectively and painlessly deliver larger molecules in therapeutic quantities to overcome the difficulties associated with the oral route. Various products of TDDS are in use by applying approaches like micro needles, abrasion, micro scission, jet delivery, iontopher's, electroportation, ultrasound and radiofrequency. The present drug delivery is highly significant if compared to oral route for less side effect, better bioavailability and longer duration of action.
引用
收藏
页码:340 / 345
页数:6
相关论文
共 19 条
[1]  
[Anonymous], 2010, INT J PHARM TECH RES
[2]  
Arunachalam A., 2010, CURR PHARMA RES, V1, P70
[3]  
Benson Heather A. E., 2005, Current Drug Delivery, V2, P23, DOI 10.2174/1567201052772915
[4]  
Bhowmik D., 2012, PHARMA INNOVATION, V1, P9
[5]  
Bhura D, 2012, PHARMA INNOVATION, V1, P66, DOI [10.20959/wjpps20174-9012, DOI 10.20959/WJPPS20174-9012]
[6]  
Jain N. K., 2005, PROGR CONTROLLED NOV, P138
[7]  
Keleb E., 2010, INT J ADV PHARM SCI, V1, P201
[8]  
Loyd V, 2005, PHARM DOSAGE FORMS D, P298
[9]  
Mahajan U., 2012, INDO GLOBAL J PHARM, V2, P262
[10]  
Mehta Nozer, 2012, RECENT ADV ROUTES DE, P1